Change of Gut Microbiota and its Role in Tuberculosis
), Cleine Michaela(2),
(1) Gastroentero-Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
(2) Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Corresponding Author
Abstract
Introduction: Tuberculosis (TB) is a prevalent infectious illness and a leading cause of death globally. An alteration in the microbial communities heightens vulnerability to tuberculosis. The changes mentioned below are responsible for pulmonary disease, as well as a decrease in the body's ability to resist the invasion of harmful external microorganisms or the depletion of beneficial bacteria.
Literature review: Adults diagnosed with pulmonary tuberculosis exhibited a stool microbiome that contained a greater abundance of anaerobic microorganisms. This was found to be linked to proinflammatory immunological pathways in the host and was also associated with the severity of tuberculosis. Relapsed tuberculosis was correlated with elevated Actinobacteria and Proteobacteria levels and decreased Bacteroidetes levels. The pathogenesis of Mycobacterium TB infection and the onset of tuberculosis symptoms may be influenced by changes in the gut-lung microbiome axis. Medication availability, efficacy, and adverse effects can be impacted by the gut flora in several ways. Currently, researchers recommend exploring the potential of combining TB medicine with gut-focused probiotics to improve treatment response and outcomes.
Conclusion: The microbiome has the potential to be a modifiable risk factor for tuberculosis. The human microbiota may have a role in the development of M. tuberculosis and treatment for tuberculosis can disrupt the balance of microorganisms, leading to dysbiosis, which can in turn impact the host's immune system. Probiotics and postbiotics demonstrate anti-tuberculosis properties, suggesting their ability to address problems arising from the use of various antibiotics.
Keywords: Tuberculosis, microbiome, gut-lung axis
Keywords
References
WHO. Global tuberculosis report 2020 [Internet]. [cited 2024 Jan 19]. Available from: https://www.who.int/publications-detail-redirect/9789240013131
Salameh M, Burney Z, Mhaimeed N, Laswi I, Yousri NA, Bendriss G, et al. The role of gut microbiota in atopic asthma and allergy, implications in the understanding of disease pathogenesis. Scand J Immunol. 2020;91(3):e12855.
Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017 May;15(5):259–70.
Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. PLOS Pathog. 2021 Apr 15;17(4):e1009377.
Shah T, Shah Z, Baloch Z, Cui X. The role of microbiota in respiratory health and diseases, particularly in tuberculosis. Biomed Pharmacother Biomedecine Pharmacother. 2021 Nov;143:112108.
Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut–lung axis. Nat Rev Microbiol. 2017 Jan;15(1):55–63.
Naidoo CC, Nyawo GR, Sulaiman I, Wu BG, Turner CT, Bu K, et al. Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis. EBioMedicine. 2021 May;67:103374.
Li W, Zhu Y, Liao Q, Wang Z, Wan C. Characterization of gut microbiota in children with pulmonary tuberculosis. BMC Pediatr. 2019 Nov 18;19(1):445.
Namasivayam S, Sher A, Glickman MS, Wipperman MF. The Microbiome and Tuberculosis: Early Evidence for Cross Talk. mBio. 2018 Sep 18;9(5):10.1128/mbio.01420-18.
Vorkas CK, Wipperman MF, Li K, Bean J, Bhattarai SK, Adamow M, et al. Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight [Internet]. 2018 Oct 4 [cited 2024 Jan 19];3(19). Available from: https://insight.jci.org/articles/view/121899
Comberiati P, Di Cicco M, Paravati F, Pelosi U, Di Gangi A, Arasi S, et al. The Role of Gut and Lung Microbiota in Susceptibility to Tuberculosis. Int J Environ Res Public Health. 2021 Nov 21;18(22):12220.
Arias L, Goig GA, Cardona P, Torres-Puente M, Díaz J, Rosales Y, et al. Influence of Gut Microbiota on Progression to Tuberculosis Generated by High Fat Diet-Induced Obesity in C3HeB/FeJ Mice. Front Immunol [Internet]. 2019 [cited 2024 Jan 19];10. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02464
Hu Y, Yang Q, Liu B, Dong J, Sun L, Zhu Y, et al. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs. J Infect. 2019 Apr 1;78(4):317–22.
Luo M, Liu Y, Wu P, Luo DX, Sun Q, Zheng H, et al. Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis. Front Physiol [Internet]. 2017 [cited 2024 Jan 19];8. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2017.00822
Eribo OA, du Plessis N, Ozturk M, Guler R, Walzl G, Chegou NN. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? Cell Mol Life Sci. 2020;77(8):1497–509.
Naidoo CC, Nyawo GR, Wu BG, Walzl G, Warren RM, Segal LN, et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. Lancet Respir Med. 2019 Oct 1;7(10):892–906.
Hu Y, Feng Y, Wu J, Liu F, Zhang Z, Hao Y, et al. The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients. Front Cell Infect Microbiol [Internet]. 2019 [cited 2024 Jan 19];9. Available from: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00090
Majlessi L, Sayes F, Bureau JF, Pawlik A, Michel V, Jouvion G, et al. Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis. Mucosal Immunol. 2017 Sep 1;10(5):1178–89.
Diallo D, Somboro AM, Diabate S, Baya B, Kone A, Sarro YS, et al. Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies. Front Cell Infect Microbiol. 2021 Dec 7;11:673100.
Swanson HI. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry? Drug Metab Dispos. 2015 Oct;43(10):1499–504.
Negi S, Pahari S, Bashir H, Agrewala JN. Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice. Eur J Immunol. 2020;50(12):1976–87.
Hancock REW, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012 Apr;10(4):243–54.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506–14.
Bravo M, Combes T, Martinez FO, Cerrato R, Rey J, Garcia-Jimenez W, et al. Lactobacilli Isolated From Wild Boar (Sus scrofa) Antagonize Mycobacterium bovis Bacille Calmette-Guerin (BCG) in a Species-Dependent Manner. Front Microbiol [Internet]. 2019 [cited 2024 Jan 19];10. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01663
Lokesh D, Rajagopal K, Shin JH. Multidrug Resistant Probiotics as an Alternative to Antibiotic Probiotic therapy. J Infect Epidemiol [Internet]. 2019 Nov 20 [cited 2024 Jan 19];2(4). Available from: https://www.infectiologyjournal.com/articles/multidrug-resistant-probiotics-as-an-alternative-to-antibiotic-probiotic-therapy.html
Lokesh D, Parkesh R, Kammara R. Bifidobacterium adolescentis is intrinsically resistant to antitubercular drugs. Sci Rep. 2018 Aug 9;8(1):11897.
Article Metrics
Abstract View
: 208 times
Download : 192 times
DOI: 10.24871/2522024336
Refbacks
- There are currently no refbacks.
